Levophenacylmorphan is the synthetic narcotic analgesic and sedative agent. Levophenacylmorphan have been used as pre-anaesthetic medication. Phenazocine and levophenacylmorphan have similar pharmacologic properties and similar analgesic potency. Levophenacylmorphan is under international control according to the UN Single Convention 1961 and its amendments. It is not found in any pharmaceutical preparations sold in the United States.

Stilonium Iodide (also known as MG 624) is a trimethylethanaminium derivative with ganglionic-blocking action. Stilonium Iodide acts as α7-nicotinic receptor antagonist and Stilonium Iodide inhibits transmission between preganglionic and postganglionic neurons in the Autonomic Nervous System. Stilonium Iodide inhibits nicotine-induced proliferation and angiogenesis in human microvascular endothelial cells of the lung. Stilonium Iodide displayed anti-angiogenic activity in Matrigel, rat aortic ring and rat retinal explant assays. Furthermore, MG624 suppressed angiogenesis of NCI-H69 human SCLC tumors in vivo in both the chicken chorioallantoic membrane (CAM) and nude mice model.

Ormaplatin (NSC 363812, tetraplatin) is a stable platinum (IV) analog. Ormaplatin alkylates DNA, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. Ormaplatin showed marked antitumor activity both in vitro and vivo. The severe, cumulative and irreversible peripheral neurotoxicity observed in phase I studies resulted in termination of further clinical development of ormaplatin.

Resolvin E1 (RvE1 or RX-10001) is a trihydroxy eicosapentaenoic acid metabolite that has a role as an anti-inflammatory agent and a human xenobiotic metabolite. This compound binds to leukotriene B4 (BLT-1) on neutrophils and to ERV-1/ChemR23 on monocyte/macrophages. Resolvin E1 has been shown to reverse experimental periodontitis and dysbiosis in rats. Furthermore, in a murine model of Alzheimer’s disease, Resolvin E1 (in combination with lipoxin A4) decreased neuroinflammation. Resolvin E1 was also suggested as a potential therapeutic target for psoriasis. A phase I clinical trial to test drug safety in healthy volunteers has been completed in 2009.